KR100985502B1 - 피라졸 유도체,그것을 함유하는 의약 조성물, 그 의약용도 및 그 제조 중간체 - Google Patents

피라졸 유도체,그것을 함유하는 의약 조성물, 그 의약용도 및 그 제조 중간체 Download PDF

Info

Publication number
KR100985502B1
KR100985502B1 KR1020057002286A KR20057002286A KR100985502B1 KR 100985502 B1 KR100985502 B1 KR 100985502B1 KR 1020057002286 A KR1020057002286 A KR 1020057002286A KR 20057002286 A KR20057002286 A KR 20057002286A KR 100985502 B1 KR100985502 B1 KR 100985502B1
Authority
KR
South Korea
Prior art keywords
group
methyl
alkyl
pyrazole
isopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020057002286A
Other languages
English (en)
Korean (ko)
Other versions
KR20050059067A (ko
Inventor
히로타카 데라니시
노부히코 후시미
시게루 요네쿠보
가즈오 시미즈
도시히데 시바자키
마사유키 이사지
Original Assignee
깃세이 야쿠힌 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 깃세이 야쿠힌 고교 가부시키가이샤 filed Critical 깃세이 야쿠힌 고교 가부시키가이샤
Publication of KR20050059067A publication Critical patent/KR20050059067A/ko
Application granted granted Critical
Publication of KR100985502B1 publication Critical patent/KR100985502B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020057002286A 2002-08-08 2003-08-07 피라졸 유도체,그것을 함유하는 의약 조성물, 그 의약용도 및 그 제조 중간체 Expired - Fee Related KR100985502B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JPJP-P-2002-00232074 2002-08-08
JP2002232074 2002-08-08
JPJP-P-2002-00321729 2002-11-05
JP2002321729 2002-11-05

Publications (2)

Publication Number Publication Date
KR20050059067A KR20050059067A (ko) 2005-06-17
KR100985502B1 true KR100985502B1 (ko) 2010-10-05

Family

ID=31719857

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057002286A Expired - Fee Related KR100985502B1 (ko) 2002-08-08 2003-08-07 피라졸 유도체,그것을 함유하는 의약 조성물, 그 의약용도 및 그 제조 중간체

Country Status (18)

Country Link
US (2) US7375087B2 (enExample)
EP (1) EP1544208B1 (enExample)
JP (1) JP4540475B2 (enExample)
KR (1) KR100985502B1 (enExample)
AT (1) ATE469161T1 (enExample)
AU (1) AU2003254847B2 (enExample)
BR (1) BRPI0313290B1 (enExample)
CA (1) CA2494179C (enExample)
DE (1) DE60332743D1 (enExample)
ES (1) ES2345250T3 (enExample)
IL (1) IL166748A0 (enExample)
MX (1) MXPA05001549A (enExample)
NO (1) NO330456B1 (enExample)
NZ (1) NZ538117A (enExample)
PL (1) PL213095B1 (enExample)
RU (1) RU2356906C2 (enExample)
TW (1) TW200413401A (enExample)
WO (1) WO2004014932A1 (enExample)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000025598A1 (en) 1998-11-03 2000-05-11 Dandy A/S Sucrose fatty acid esters for use as increased release of active ingredients
AU2003254847B2 (en) * 2002-08-08 2009-06-04 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
JP2004137245A (ja) * 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
JP4606876B2 (ja) * 2002-08-27 2011-01-05 キッセイ薬品工業株式会社 ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途
US20060035844A1 (en) * 2002-12-04 2006-02-16 Fumiaki Ito Preventive or remedy for diseases caused by hyperglycemia
EP1577317A4 (en) * 2002-12-25 2007-05-09 Kissei Pharmaceutical NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES, MEDICINAL COMPOSITIONS COMPRISING SAID DERIVATIVES AND MEDICAL USE OF SAID DERIVATIVES
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
DE102004028241B4 (de) * 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
CA2588963C (en) * 2004-11-18 2013-06-25 Kissei Pharmaceutical Co., Ltd. 1-substituted-3-.beta.-d-glucopyranosylated nitrogenous hetero-cyclic compounds and medicines containing the same
FR2878523B1 (fr) * 2004-11-30 2007-09-14 Oreal Nouveaux derives sulfamides et leur utilisation cosmetique
US7887824B2 (en) 2004-11-30 2011-02-15 L'oreal Sulfamide derivatives and cosmetic use thereof
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
WO2007010015A1 (en) * 2005-07-22 2007-01-25 Boehringer Ingelheim International Gmbh Processes for preparing pyrazole-o-glycoside derivatives and novel intermediates of said processes
WO2007025880A2 (en) * 2005-08-31 2007-03-08 F. Hoffmann-La Roche Ag Pyrazolone derivatives as 11-beta hsd1 inhibitors
UY30082A1 (es) 2006-01-11 2007-08-31 Boehringer Ingelheim Int Forma cristalina de 1-(1-metiletil)-4`-((2-fluoro-4-metoxifenil)metil)-5`- metil-1h-pirazol-3`-o-b-d-glucopiranosido, un metodo para su preparacion y el uso de la misma para preparar medicamentos
JP2009167103A (ja) * 2006-05-02 2009-07-30 Taisho Pharmaceutical Co Ltd ピラゾリル５−チオグリコシド化合物
PE20080697A1 (es) * 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
BRPI0711949A2 (pt) 2006-05-19 2012-01-17 Taisho Pharmaceutical Co., Ltd. composto c-fenil glicitol
WO2007140191A2 (en) 2006-05-23 2007-12-06 Theracos, Inc. Glucose transport inhibitors and methods of use
KR20090023570A (ko) 2006-06-29 2009-03-05 다이쇼 세이야꾸 가부시끼가이샤 Ｃ-페닐 1-티오글루시톨 화합물
RU2009126767A (ru) 2006-12-14 2011-01-20 Тайсо Фармасьютикал Ко., Лтд. (Jp) Производное 1-фенил-1-тио-d-глюцитола
AU2008232419B2 (en) * 2007-04-02 2013-06-20 Theracos, Inc. Benzylic glycoside derivatives and methods of use
RU2355396C2 (ru) * 2007-07-09 2009-05-20 Государственное учреждение Научно-исследовательский институт акушерства, гинекологии и перинатологии Томского научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ АГиП ТНЦ СО РАМН) Средство и способ профилактики гемореологических нарушений у беременных со стертыми формами гиперандрогении и фето-плацентарной недостаточностью
PE20090938A1 (es) * 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
NZ583369A (en) 2007-08-23 2011-08-26 Theracos Inc Benzylbenzene derivatives and methods of use
UA101004C2 (en) 2007-12-13 2013-02-25 Теракос, Инк. Derivatives of benzylphenylcyclohexane and use thereof
BRPI0821773B8 (pt) * 2007-12-27 2021-05-25 Kissei Pharmaceutical monossebacato cristalino de bis[3-(3-{4-[3-(beta-dglicopiranosilóxi)-5-isopropil-1h-pirazol-4-ilmetil]-3-metilfenóxi}propilamino)-2,2-dimetil-propionamida], composição farmacêutica e medicamento compreendendo o dito composto
PL2324002T3 (pl) * 2008-08-22 2017-03-31 Theracos Sub, Llc Sposoby otrzymywania inhibitorów sglt2
CN102149717B (zh) * 2008-08-28 2014-05-14 辉瑞大药厂 二氧杂-双环[3.2.1]辛烷-2，3，4-三醇衍生物
PE20120017A1 (es) 2009-02-13 2012-02-12 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de sglt2, un inhibidor de dpp-iv, opcionalmente, un agente antidiabetico adicional, y sus usos
US8466113B2 (en) 2009-02-23 2013-06-18 Taisho Pharmaceutical Co., Ltd. 4-isopropylphenyl glucitol compounds as SGLT1 inhibitors
EP2298782A1 (en) * 2009-08-26 2011-03-23 Sanofi-Aventis Method for producing pyrazole glycoside derivatives
AU2010295722B2 (en) * 2009-09-15 2015-04-16 Janssen Pharmaceutica, N.V. Use of alpha-methylglucoside (AMG) as an indicator for glucose absorption and excretion
CA2775962C (en) * 2009-09-30 2017-09-05 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
EA020798B1 (ru) * 2009-09-30 2015-01-30 Бёрингер Ингельхайм Интернациональ Гмбх СПОСОБ ПОЛУЧЕНИЯ КРИСТАЛЛИЧЕСКОЙ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА
US10610489B2 (en) * 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
CN102753184A (zh) 2009-10-02 2012-10-24 赛诺菲 具有sglt-1/sglt-2抑制剂活性的化合物在制备用于治疗骨病的药物中的用途
PL2496583T3 (pl) 2009-11-02 2015-04-30 Pfizer Pochodne dioksabicyklo[3.2.1]oktano-2,3,4-triolowe
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
JP6042330B2 (ja) 2010-07-09 2016-12-14 ビーエイチヴィ ファーマ、インコーポレイテッド レモグリフロジンを含めた半減期が短い医薬品のための組合せ即時／遅延放出送達システム
JP2013224263A (ja) * 2010-08-19 2013-10-31 Taisho Pharmaceutical Co Ltd ４−イソプロピルフェニルグルシトール化合物
US8822674B2 (en) 2010-08-20 2014-09-02 Taisho Pharmaceutical Co., Ltd Crystal form of 4-isopropylphenyl glucitol compound and process for production thereof
US9161945B2 (en) 2010-08-20 2015-10-20 Taisho Pharmaceutical Co., Ltd. 4-isopropyl-6-methoxyphenyl glucitol compound
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
WO2012176804A1 (ja) * 2011-06-20 2012-12-27 キッセイ薬品工業株式会社 グルコピラノシルオキシピラゾール誘導体
PH12013502695A1 (en) 2011-07-01 2019-06-14 Bayer Ip Gmbh Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US9193751B2 (en) 2012-04-10 2015-11-24 Theracos, Inc. Process for the preparation of benzylbenzene SGLT2 inhibitors
UA113086C2 (xx) * 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1
TW201425326A (zh) * 2012-10-05 2014-07-01 Lilly Co Eli 新穎脲化合物
JP5807767B2 (ja) 2013-02-04 2015-11-10 大正製薬株式会社 便秘症の予防又は治療薬
EP2774619B1 (de) 2013-03-04 2016-05-18 BioActive Food GmbH Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HK1213818A1 (zh) 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 依帕列净的治疗用途
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
ES2702174T3 (es) 2013-04-05 2019-02-27 Boehringer Ingelheim Int Usos terapéuticos de empagliflozina
JP2016520564A (ja) 2013-04-18 2016-07-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物、治療方法及びその使用
CN105611920B (zh) 2013-10-12 2021-07-16 泰拉科斯萨普有限责任公司 羟基-二苯甲烷衍生物的制备
AR098670A1 (es) * 2013-11-08 2016-06-08 Lilly Co Eli Inhibidor de sglt1
EP2944311A1 (de) 2014-05-16 2015-11-18 BioActive Food GmbH Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
MX2019005435A (es) 2016-11-10 2019-07-10 Boehringer Ingelheim Int Composicion farmaceutica, metodos para tratamiento y sus usos.
CN110054657B (zh) * 2018-01-18 2021-06-29 亚宝药业集团股份有限公司 吡喃葡萄糖取代的吡唑化合物及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001016147A1 (en) 1999-08-31 2001-03-08 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
US20050274111A1 (en) * 2004-06-14 2005-12-15 Toyota Jidosha Kabushiki Kaisha Stirling engine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2319280A1 (de) * 1973-04-17 1974-11-07 Bayer Ag 1-substituierte pyrazolone-(5), verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
CA1083335A (en) * 1976-05-10 1980-08-12 Chemed Corporation Composition and method of inhibiting corrosion
US5274111A (en) * 1992-04-07 1993-12-28 American Home Products Corporation Trifluoromethyl substituted 1H-pyrazoles and derivatives thereof
KR20010023237A (ko) 1997-08-27 2001-03-26 다케다 야쿠힌 고교 가부시키가이샤 서방성 경구 제제
WO1999026606A2 (en) 1997-11-25 1999-06-03 Bayer Aktiengesellschaft SUSTAINED RELEASE FORMULATIONS COMPRISING α-GLUCOSIDASE-INHIBITORS
CA2369871A1 (en) * 1999-04-06 2000-10-12 Takashi Fujita .alpha.-substituted carboxylic acid derivatives
JP2001002567A (ja) 1999-04-20 2001-01-09 Takeda Chem Ind Ltd 水溶性薬物を含有する徐放性製剤
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
ES2337127T3 (es) * 2000-11-02 2010-04-21 Ajinomoto Co., Inc. Nuevos derivados de pirazol y remedios contra la diabetes que los contienen.
HU228915B1 (en) * 2000-12-28 2013-06-28 Kissei Pharmaceutical Glucopyranosyloxypyrazole derivatives and use thereof
AU2003254847B2 (en) * 2002-08-08 2009-06-04 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
JP2004137245A (ja) * 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
EP1550668A4 (en) * 2002-10-04 2008-10-01 Kissei Pharmaceutical PYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION COMPRISING THE DERIVATIVE, MEDICINAL USE THEREOF, AND INTERMEDIATE ENTERING THE PRODUCTION THEREOF

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001016147A1 (en) 1999-08-31 2001-03-08 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
US20050274111A1 (en) * 2004-06-14 2005-12-15 Toyota Jidosha Kabushiki Kaisha Stirling engine

Also Published As

Publication number Publication date
BRPI0313290B1 (pt) 2016-12-06
US7655632B2 (en) 2010-02-02
NO330456B1 (no) 2011-04-18
AU2003254847A1 (en) 2004-02-25
DE60332743D1 (de) 2010-07-08
RU2356906C2 (ru) 2009-05-27
JP4540475B2 (ja) 2010-09-08
TW200413401A (en) 2004-08-01
AU2003254847B2 (en) 2009-06-04
JPWO2004014932A1 (ja) 2005-12-02
EP1544208A1 (en) 2005-06-22
BR0313290A (pt) 2005-07-05
TWI341843B (enExample) 2011-05-11
ES2345250T3 (es) 2010-09-20
EP1544208B1 (en) 2010-05-26
US20080312153A1 (en) 2008-12-18
PL375473A1 (en) 2005-11-28
EP1544208A4 (en) 2007-05-02
US7375087B2 (en) 2008-05-20
IL166748A0 (en) 2006-01-15
CA2494179A1 (en) 2004-02-19
KR20050059067A (ko) 2005-06-17
CA2494179C (en) 2012-04-24
RU2005106259A (ru) 2005-08-27
HK1082743A1 (zh) 2006-06-16
US20060166899A1 (en) 2006-07-27
PL213095B1 (pl) 2013-01-31
NO20051209L (no) 2005-04-15
ATE469161T1 (de) 2010-06-15
MXPA05001549A (es) 2005-05-05
WO2004014932A1 (ja) 2004-02-19
NZ538117A (en) 2007-01-26

Similar Documents

Publication Publication Date Title
KR100985502B1 (ko) 피라졸 유도체,그것을 함유하는 의약 조성물, 그 의약용도 및 그 제조 중간체
KR100985504B1 (ko) 피라졸 유도체, 그것을 함유하는 의약조성물, 그 의약용도및 그 제조중간체
JP4758964B2 (ja) グルコピラノシルオキシピラゾール誘導体の医薬用途
JP4606876B2 (ja) ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途
US7998975B2 (en) Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
KR101214433B1 (ko) 축합 헤테로환 유도체, 그것을 함유하는 의약 조성물 및 그의약 용도
KR101141558B1 (ko) 축합 복소환 유도체, 그것을 함유하는 의약 조성물 및 그의약 용도
JP4708187B2 (ja) ピラゾール誘導体、それを含有する医薬組成物及びその製造中間体
JP4651934B2 (ja) ベンジルフェノール誘導体、それを含有する医薬組成物およびその医薬用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20130723

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20140709

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20150713

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20170930

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20170930